CNV1014802 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Trigeminal Neuralgia
Conditions
Trigeminal Neuralgia
Trial Timeline
Mar 31, 2012 → Jun 30, 2014
NCT ID
NCT01540630About CNV1014802 + Placebo
CNV1014802 + Placebo is a phase 2 stage product being developed by Biogen for Trigeminal Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT01540630. Target conditions include Trigeminal Neuralgia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02359344 | Phase 1 | Completed |
| NCT01540630 | Phase 2 | Completed |
| NCT01561027 | Phase 2 | Completed |
Competing Products
7 competing products in Trigeminal Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab | Eli Lilly | Approved | 85 |
| Erenumab-Aooe | Amgen | Phase 2 | 51 |
| Rimegepant + Placebo | Pfizer | Phase 2 | 51 |
| BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment D | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 1 | 30 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |